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Abstract
Schistosomiasis is a prevalent and chronic helmintic disease in tropical regions. Treatment and control relies on
chemotherapy with just one drug, praziquantel and this reliance is of concern should clinically relevant drug resistance
emerge and spread. Therefore, to identify potential target proteins for new avenues of drug discovery we have taken a
comparative chemogenomics approach utilizing the putative proteome of Schistosoma mansoni compared to the
proteomes of two model organisms, the nematode, Caenorhabditis elegans and the fruitfly, Drosophila melanogaster. Using
the genome comparison software Genlight, two separate in silico workflows were implemented to derive a set of parasite
proteins for which gene disruption of the orthologs in both the model organisms yielded deleterious phenotypes (e.g.,
lethal, impairment of motility), i.e., are essential genes/proteins. Of the 67 and 68 sequences generated for each workflow,
63 were identical in both sets, leading to a final set of 72 parasite proteins. All but one of these were expressed in the
relevant developmental stages of the parasite infecting humans. Subsequent in depth manual curation of the combined
workflow output revealed 57 candidate proteins. Scrutiny of these for ‘druggable’ protein homologs in the literature
identified 35 S. mansoni sequences, 18 of which were homologous to proteins with 3D structures including co-crystallized
ligands that will allow further structure-based drug design studies. The comparative chemogenomics strategy presented
generates a tractable set of S. mansoni proteins for experimental validation as drug targets against this insidious human
pathogen.
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Introduction
Schistosomiasis is a parasitic disease infecting over 200 million
people [1]. Considered a ‘neglected tropical disease (NTD)’ [2] for
which, traditionally, there has been little in the way of a concerted
drug discovery program, three major species of the flatworm
parasite are responsible for disease in sub-Saharan Africa
(Schistosoma mansoni, S. haematobium), South America (S. mansoni)
and parts of China and South-East Asia (S. japonicum) [1].
Pathology associated with schistosomiasis mansoni and japonica
results primarily from the accumulation of parasite eggs over the
course of years and even decades giving rise initially to
hepatomegaly that may be superseded by extensive liver fibrosis
and possibly sequelae such as occlusion of the hepatic portal vein,
portal hypertension, and gastrointestinal varices [3]. Furthermore,
chronic schistosomiasis haematobia is a risk factor for squamous
cell carcinoma of the bladder [4]. The disease is also known for its
more subtle, and indeed underestimated [5] morbid effects,
particularly in school-aged children. These include physical and
cognitive under-performance, anemia and abdominal discomfort.
Despite ongoing attempts to produce a molecular vaccine [6,7],
present treatment and control of schistosomiasis relies on
chemotherapy [8]. Just one drug, praziquantel (PZQ), for which
the detailed mode of action is still unclear [9,10], is widely
available. Since its introduction in the late 1970’s, PZQ has
become the sole, WHO-recommended treatment, being safe,
effective and affordable [11]. PZQ’s success as a drug has
contributed to a lack of urgency and investment in identifying new
therapies, either in terms of chemical entities or molecular targets.
This over-reliance on a single therapy to treat large populations is
a serious concern regarding the potential for drug resistance
[12,13]. Resistance to PZQ has been bred on more than one
occasion in the laboratory [14] and foci of transient drug resistance
have been reported in the literature [15]. Thus, with the WHO-
backed goal to more widely disseminate PZQ (the Schistosomiasis
Control Initiative [16]), it may just be a matter of time before
clinically relevant drug resistance emerges [8].
The tenuousness of therapeutic options for schistosomiasis,
together with better knowledge of the molecular and biochemical
idiosyncrasies of the parasite, and improved genome sequence
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and validation [8,17]. Further, a completely annotated Schistosoma
mansoni genome should, in the future, provide a rich source of
information for both academia and non-profit interests to identify,
prioritize and prosecute drug and vaccine targets. In advance of
this milestone, sufficient characterization and annotation of the
genome has already taken place [18] so that in the latest Version 4
of Schistosoma mansoni GeneDB [19] the prediction of genes, open
reading frames and translation products has been accomplished.
Given the wealth of organized data to hand, therefore, we felt it
timely to put this information to work in an in silico comparative
genomics strategy to identify a subset of schistosome genes/
proteins that have potential value as drug targets in order to jump-
start focused discovery efforts. Our approach was to mine the
proteomes of the model organisms Drosophila melanogaster and
Caenorhabditis elegans for proteins with clear sequence similarities to
those in the parasite in order to identify those experimentally
proven as essential, i.e., targeted gene disruption produces
deleterious phenotypes (e.g. lethal, paralyzed, impaired of motility)
in both model organisms. Precedence has shown that even for
parasite proteins that share significant sequence similarity with
vertebrate proteins, anti-parasite drugs can, nevertheless, be
developed (e.g. b-tubulin, the target protein of benzimidazoles)
[20]. Accordingly, the 13,283 predicted gene products of S. mansoni
were compared in a semi-automatic process to the proteomes and
phenotypic databases of D. melanogaster and C. elegans using the
software Genlight [21,22]. The output of 72 potential target
proteins was manually curated leading to the identification of 35 S.
mansoni proteins with druggable characteristics. Of these, 18
belong to protein families for which extensive 3D structural
information is available, including bound small molecule ligands
and drugs. Such structural data makes these proteins particularly
suitable for prioritization of structure-based drug design strategies.
Results
Semi-automatic in silico workflows identify 72 candidate
S. mansoni gene products
For the first in silico workflow, orthologs shared between the
predicted proteome of S. mansoni [19], and the proteomes of C.
elegans and D. melanogaster available at Wormbase [23] and Flybase
[24], respectively, were determined (Figure 1A). For S. mansoni and
C. elegans, and S. mansoni and D. melanogaster, 1778 and 1927
orthologs were identified, respectively. A subsequent comparison
of both outputs demonstrated that 1258 sequences were identical.
By reciprocal blastp [25,26], this set was then compared with the
phenotype databases of C. elegans (Caltech server) [23] and D.
melanogaster [24], and those orthologs displaying the appropriate,
pre-set, mutant phenotypes identified. The S. mansoni sequences of
both ortholog sets were pooled and only those proteins with a
100% sequence identity were considered as potential target
proteins. Altogether, 68 S. mansoni sequences with orthologs in C.
elegans and D. melanogaster were identified.
To evaluate the performance and results of the first in silico
approach, a second workflow was generated (Figure 1B). First,
orthologs shared between C. elegans and D. melanogaster were
identified. The different numbers of orthologs (2933 in C. elegans
compared to 3789 in D. melanogaster) are due to the high occurrence
of identical gene copies with different identifiers in Flybase. Thus,
certain C. elegans genes generate multiple hits in D. melanogaster. The
orthologs from both model organisms were then separately
compared with the S. mansoni putative proteome resulting in 1502
orthologs shared between C. elegans and S. mansoni, and 1520
orthologs between D. melanogaster and S. mansoni. A redundancy
check of these individual outputs established that 1302 sequences
were identical. These 1302 sequences were then pooled with the
extra non-redundant sequences (150221302=200 and
152021302=218 from the C. elegans and D. melanogaster compar-
isons, respectively) to give a total of 1720 S. mansoni sequences. By
reciprocal blastp and using the pre-set, mutant phenotype criteria,
orthologs of these sequences in the phenotype databases of C. elegans
and D. melanogaster were determined. Comparison of these outputs
identified 67 potential S. mansoni target proteins that have orthologs
in both model organisms. Finally, the sequence outputs from both in
silico workflows (68 and 67 sequences, respectively) were compared
in order to determine the extent to which they were identical
(Figure 1C). Sixty-three proteins were shared, thus demonstrating
the reliability of the software and the compatibility of the workflows.
Overall, by adding the 63 shared proteins to the 5 and 4 extra
sequences exclusive to the first and second workflows, respectively,
72 S. mansoni proteins wereconsidered for furthermanualfiltering in
order to delineate potential drug targets.
Manual curation identifies 35 potential drug targets in S.
mansoni
Manual scrutiny of the 72 sequences generated by the semi-
automatic workflows was considered essential in order to remove
possible redundant information and improve overall confidence in
the results (Figure 1, Table 1). Each curation step is represented by
a separate worksheet in Table S1.
First, duplicates of four sequence entries (Smp_062300 «
Smp_062300.2, Smp_103470.3 « Smp_103470.4, Smp_120700.1
« Smp_120700.2, and Smp_138970.1 « Smp_138970.4) were
removed to leave 68 sequences. Subsequently, three sequences
(Smp_028990.1, Smp_124240, and Smp_138970.1), not confirmed
as the definitive schistosome orthologs after reciprocal blastp with
both Wormbase and Flybase, were removed to produce 65
sequences. Next, seven of these sequences for which deleterious
phenotypes (e.g. lethal,paralyzed, movement abnormal,etc.)couldnot
be confirmed for the respective orthologs or for which the relevant
orthologous allele or phenotype information was simply unavailable
were removed. Upon scrutiny of the EST evidence (see footnote to
Table S1), one additional sequence (Smp_154270) was also removed
because it is only expressed in the miracidium – a developmental
stage not found within the human host. The remaining 57 sequences
are expressed in the relevant parasite life-stages that persist in
humans, namely, the immature schistosomulum form, either
prepared in vitro or removed from a mammalian host (in vivo), adult
(male and/or female) and egg.
Next, each of the 57 sequences was assessed for druggability that
is defined as the likelihood of being able to modulate a target’s
activity with a small-molecule drug [27,28]. We mined a number
of biological and literature databases to document whether
orthologous proteins or proteins of the same family have been
reported to be manipulated by ligands, inhibitors or even targeted
by known drugs. For 35 of the S. mansoni proteins we found
unambiguous evidence that homologous proteins are druggable
(Table 1, Table S1). Accordingly, these might be prioritized as
high value drug targets for new treatments of schistosomiasis.
Finally, we searched among the 35 S. mansoni proteins for
homologous proteins that have a 3D structure and/or a 3D
structure complexed with a ligand, inhibitor or drug. Such
structural information would enhance the druggability value by
facilitating a structure-based drug design strategy, including
homology modeling, docking, virtual screening or pharmaco-
phore-based screening [29,30]. Eighteen of the 35 S. mansoni
proteins fulfilled these conditions (Tables 1 and 2) and another 8
had at least partial 3D structure information available (Table S1).
Schistosoma mansoni
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The comparative chemogenomics strategy described herein
provides a prioritized and testable list of potential target proteins
for S. mansoni, a metazoan pathogen causing chronic and
debilitating disease in humans. The intent was first to mine the
S. mansoni genome and identify putative essential genes based on
similarity to experimentally-determined essential genes/proteins in
two model metazoans and then define a subset of potential drug
targets for which structural information of known target proteins,
including bound ligands, exist. Both the strategy and outputs are in
keeping with the recent establishment of a TDR Drug Targets
Prioritization Database [31] by the World Health Organization’s
Special Programme for Research and Training in Tropical
Diseases that facilitates the identification and prioritization of
target genes in a number of pathogenic organisms, including those
responsible for NTDs.
A number of factors were considered during the development
and execution of the workflows in order to provide both
confidence in the data generated and a solid platform from which
to predict the druggability of individual S. mansoni proteins. First,
rather than comparison with one metazoan proteome we
incorporated two into the analysis, particularly as both C. elegans
and D. melanogaster are phylogenetically remote from Schistosoma.
Secondly, we only considered those orthologous genes/proteins for
which phenotypes were generated via targeted gene mutagenesis.
We discounted orthologs with phenotypes arising from RNAi
(RNA interference) due to the potential for non-specific, off-target
effects and false positive results including with Drosophila cells
[32,33,34]. Nevertheless, the present protocol can be adapted to
include RNAi phenotypes should one wish to cast the net wider.
As a final stricture in the analysis, we selected for severely
deleterious phenotypes such as death or those involving motility
disorders with the aim of producing both a short list of testable
targets and enriching for phenotypes that should be obvious when
targeting the respective schistosome genes by chemical and/or
genetic means (see below). We would state that our strategy focuses
on potential targets based on loss-of-function and that gain-of-
function targets such as those involved in drug agonism e.g., ion
channels, will be missed. As many current anthelmintics, including
PZQ, are agonists, it would be worthwhile developing systems for
gain-of-function mutants in model organisms (for example using
targeted overexpression banks).
The present strategy differs from previous comparative genomic
screens for infectious diseases and for which the goal was to
identify potential drug targets unique to the pathogen based on a
user-prescribed similarity cut-off value in order to decrease the
potential for toxicity of any new chemotherapeutic [35,36].
Though this ‘exclusion’ approach is sound, nevertheless, examples
abound of pathogen proteins that possess considerable similarity to
human proteins and yet are valid drug targets e.g., parasite
cysteine proteases [37,38,39], and the remarkable example of the
highly conserved b-tubulin protein, the target of benzimidazoles
[20], even though they might have failed a user-prescribed
similarity cut-off as part of an exclusion genomics screen [35]. In
addition, it is often the case that drug selectivity for a pathogen
arises due to idiosyncrasies in pathogen physiology such as slower
turnover of the target protein allowing for more pronounced drug
action, e.g., ornithine decarboxylase in Trypanosoma brucei, the
causative agent of African Sleeping Sickness [40], differences in
protein regulation, e.g., dihydrofolate reductase in Plasmodium
falciparum [41] or a lack of functional redundancy compared to the
host [42]. Thus, we consider that the present similarity-based
strategy to mine the S. mansoni genome represents a useful
contribution to the consideration of new anti-schistosomal
therapeutic targets.
An important aspect of developing drugs to NTDs such as
schistosomiasis and for which profits are nil or marginal at best, is
the need to keep costs of drug development to a minimum.
Experience has shown that drug development programs for
pathogen-specific targets of often unknown function, although a
valid scientifically, are, in many cases, more expensive. Our
strategy, therefore, to identify homologous rather than pathogen-
specific potential targets is intended to reduce costs by leveraging
the biochemical, chemical and structural data and tools already
available for therapeutic targets of proven value in other clinical
contexts, i.e., ‘piggy-back’ drug discovery [43,44,45]. The finding
that 35 of the in silico-identified 72 sequences are indeed
homologous to known druggable targets supports our strategy.
Moreover, 18 of these belong to protein families for which 3D
structural information including ligands or even drugs is available
(e.g., N-(4-Methoxybenzyl)-N9-(5-Nitro-1,3-Thiazol-2-YI)Urea
and Carbidopa). This opens the route not only for classical
biochemical studies but also for structure-based drug discovery
approaches [29,46,47]. For instance, among the 18 candidate
proteins, small molecule scaffolds exist for methionine aminopep-
tidase targeting cancer [48] and malaria [49], N-myristoyl
transferase against fungal infections [50] and Rac-GTPase against
cancer [51]. The availability of specific small molecules adds
incentive to prioritizing the experimental validation of the
orthologous schistosome proteins.
Unlike for both model organisms, standardized functional
genomic tools, such as targeted gene disruption or gene ‘knock-
Table 1. Automatic and manual filtering for potential target
proteins
Filter
Number of S.
mansoni proteins
Comparative Genomics 72
Manual Curation* 57
Druggable Targets based on surveys of literature and
biological databases
35
3D Structure with co-crystallized ligand 18
*Removal of sequences that were redundant, not confirmed as the ortholog by
reciprocal blastp, for which a phenotype was not confirmed or not expressed
in the relevant life stages that persist in the human host. Numbers correspond
to those on the tabs in the Microsoft Excel-worksheets provided in Table S1.
doi:10.1371/journal.pone.0004413.t001
Figure 1. In silico workflows to identify putative drug target proteins in S. mansoni based on sequence and phenotype comparisons.
A and B, representations of two independent workflows leading to a similar number of potential targets. C, the combination of workflows A and B
generating a final number of 72 sequences (octagon) of which 63 were identical. Numbers of sequences used in each step are indicated within the
respective circles. Depending on the intersection, the numbers within represent either sequence orthologs or S. mansoni proteins for which a
deleterious phenotype is recorded in either Wormbase or Flybase. Blue, red and yellow circles display sequences from C. elegans (Ce), D. melanogaster
(Dm), and S. mansoni (Sm), respectively. Details of the workflows are described in the text.
doi:10.1371/journal.pone.0004413.g001
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represents a stumbling block for interrogating gene function with
confidence. However, transient RNAi with double stranded RNAi
or small interfering (si)RNA has gained a foothold as a useful
technique for gene knock down (if not knock out), including in
those developmental stages relevant to infection and pathology in
humans (somules, adults and eggs) [52,53]. We would assume,
therefore, that transient RNAi will be an important tool to
experimentally establish gene essentiality until more rigorous
reverse genetic techniques become established. Where available, a
complementary strategy to RNAi would be to employ a chemical
genetics approach using protein-selective small molecules (see
examples above). Such an approach has already been validated
regarding schistosome cysteine proteases [37] and enzymes
involved in redox metabolism [54].
We have mined and compared the predicted proteome of the
metazoan pathogen, S. mansoni,with those of two well-studied
model organisms in order to identify potential drug targets. The
chemogenomics strategy has produced a tractable list of prioritized
genes for further investigation, one or more of which might
contribute to badly-needed drug discovery programs for this
prevalent human disease.
Methods
Datasets
All protein datasets are available on Flybase (version
FB2006_01) [24], Wormbase release 195 [23], and Schistosoma
mansoni GeneDB v4.0 [19]. The D. melanogaster phenotype database
was generated using the Flybase QueryBuilder. All proteins with
the mutant phenotypes ‘‘lethal’’ and/or ‘‘neurophysiology defec-
tive’’ were downloaded. Similarly, the C. elegans phenotype
database was generated using the Caltech server based on
Wormbase release 177 [23]. All proteins with the mutant
phenotypes ‘‘lethal’’, ‘‘paralyzed’’, ‘‘movement abnormal’’ and/
or ‘‘muscle system physiology abnormal’’ were downloaded.
However, only data from knock-out mutants (alleles) were used;
RNAi phenotypes were excluded due to the potential for non-
specific effects [32,33,34].
Comparative Genomics using Genlight
All genome comparisons performed were based on translated
genomes using the software Genlight [21], for which a public
WWW-server is available at the University of Bielefeld, Germany
[22]. Genlight is a client/server based program suite developed for
large scale sequence analyses and comparative genomics calcula-
tions. A key functionality of Genlight is the determination of
orthologs via reversed or reciprocal blast searches. Sequences from
organism A are compared with those from organism B and vice
versa using the respective blast program [25,26]. Orthologous
sequences are then defined as those best hit sequences that find
each other in such bidirectional blast searches. The sequence
alignment overlap and the E-value cut off can be preset in
accordance with the goal of the experiment [21,29]. Within
Genlight, we defined orthologs as best reciprocal blastp hits with a
minimum of 70% sequence alignment overlap and an E-value of
0.01 or smaller.
A useful feature of the Genlight software is its user friendliness in
the post-processing of results including the employment of
predefined filters and operations. For example, result sets can be
re-used directly to exclude duplicates in order to generate non-
redundant datasets. This feature has been employed as described
in the two in silico workflows (Figure 1) and resulted in the
identification of 72 potential target proteins in the S. mansoni
predicted proteome (Table S1) for which deleterious phenotypes
were identified for the respective orthologs in both C. elegans and D.
melanogaster.
Table 2. Druggable target proteins belonging to protein families with 3D structural information, including co-crystallized ligands
S. mansoni Putative Protein
Molecular Function GO Annotation at Schistosoma mansoni
GeneDB [19] GeneDB Accession Number
GTP-binding protein GTP binding, signal transducer activity Smp_005790
Glycogen synthase kinase 3 related ATP binding, protein kinase activity Smp_008260.1
Methionine amino peptidase Metallo exopeptidase activity Smp_011120
Calmodulin dependent protein kinase II Protein kinase activity Smp_011660.2
Protein phosphatase-2a Hydrolase activity Smp_030710
Nuclear transport factor Transporter activity Smp_037700
Vesicular-fusion protein nsf ATP-binding, nucleoside triphosphatase activity, nucleotide binding Smp_057320
Rac GTPase GTP-binding Smp_062300
Elongation factor tu GTP-binding, translation elongation factor activity Smp_073500.1
Neuroendocrine convertase Subtilase activity Smp_077980
Myosin heavy chain Motor activity Smp_085540.6
Nucleoside diphosphate kinase ATP-binding, nucleoside diphosphate kinase activity Smp_092750
Rab GDB-dissociation inhibitor Rab GDP-dissociation inhibitor activity Smp_094420
Heat shock protein 70 ATP-binding Smp_106130.2
N-myristoyl transferase Glycylpeptide N-tetradecanoyltransferase activity Smp_121420
Choline o-acyltransferase Acyltransferase activity Smp_146910
Rab 6 GTP-binding Smp_163580
Amino acid decarboxylase Carboxy lyase activity Smp_171580
Additional information such as key references reviewing druggability are available in Supplementary Table S1.
doi:10.1371/journal.pone.0004413.t002
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After executing two separate electronic workflows (see Figure 1),
we manually curated the schistosome protein sequence output for
consistency with our goal of identifying potential drug targets.
First, redundant sequences were removed from the dataset.
Further curation included removal of sequences (i) not confirmed
as orthologs by reciprocal blastp searches with both Wormbase
and Flybase, (ii) for which targeted gene disruption of the
appropriate ortholog does not yield a deleterious phenotype, and
(iii) which, based on the available EST evidence, are not expressed
in the relevant parasite developmental stages infecting humans
(i.e., schistosomulum (immature worm) either prepared in vitro or
removed from a mammalian host (in vivo), adult (male and/or
female) and egg). Consideration was also given to the potential
druggability of the parasite protein by manually mining biological
and literature databases on the internet including DrugBank
[55,56], UniProt [57,58], Prosite [59,60], OMIM [61,62],
InterPro [63,64] and Pfam [65,66]. Druggability was defined as
the likelihood of being able to modulate the activity of the protein
target with a small-molecule drug [27,28]. Finally, the PDB
database [67] was searched for 3D structural information of
proteins homologous to each parasite protein, including co-
crystallized ligands. The 72 sequences, together with the
subsequent manual curation steps, are presented in Table S1.
Supporting Information
Table S1 This table shows the output and manual curation of
potential S. mansoni drug targets generated by comparative
genomics with Caenorhabditis elegans and Drosophila melanoga-
ster. The table comprises 7 worksheets each with a different level
of information for the respective sequence lists. Leftmost in the
table, the first worksheet contains the 72 sequences generated from
the two separate electronic workflows utilizing the genome
comparison software, Genlight. Each worksheet thereafter repre-
sents a subsequent manual curation step involving the removal of
sequences (i) that are redundant (remaining 68 non-redundant
entries), (ii) that are not confirmed as orthologs by reciprocal blastp
searches with both Wormbase and Flybase (remaining 65
confirmed orthologs), (iii) for which targeted gene disruption of
the appropriate ortholog does not yield a deleterious phenotype as
declared in both Wormbase and Flybase (remaining 58 confirmed
phenotypes), (iv) that are not expressed in the relevant develop-
mental stages of the parasite infecting humans (remaining 57
expressed in the relevant life stage; for an explanation of how this
was performed see below), (v) that are not druggable as indicated
by manual mining of the biological and literature databases
available on the internet (remaining 35 druggable targets), and (vi)
for which homologous proteins with 3D structural information
(including co-crystallized ligands) was not found (remaining 18
proteins with both a 3D structure and co-crystallized ligand). To
determine in which developmental stage a putative protein is
expressed, the following procedure was performed. In the S.
mansoni genome browser [68], the sequence name (e.g.,
Smp_000040) is imputed into the text field, ‘‘landmark or region’’.
On the returned search page, the graphic produced by the latest
GeneDB working model and displaying the organization of the
gene is clicked to reveal a variety of information, including exon/
intron junctions, physicochemical characteristics of the putative
protein and gene ontology. Activating the hyperlink ‘‘DNA’’
reveals the unspliced DNA, spliced DNA and amino acid
sequences. Next, a blastn search at NCBI of the spliced sequence
is performed via the hyperlink ‘‘Send to BLAST at NCBI’’. The
analysis is constrained using the search set ‘non-human, non-
mouse ESTs (EST_others)’, the organism ID number of 6183 for
S. mansoni (taxid:6183) and the program selection set to
‘somewhat similar sequences’. On the EST list returned, each
accession is scrutinized for its life-stage origin by activating the
relevant link. The lowest maximum score accepted for consider-
ation was 250. Lower scores tended to be too short to be reliably
ascribed to the gene under study.
Found at: doi:10.1371/journal.pone.0004413.s001 (0.26 MB
XLS)
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